Patents by Inventor Jeffrey A. Robl

Jeffrey A. Robl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic containing biphenyl aP2 inhibitors and method
    Publication number: 20030199563
    Abstract: aP2 inhibiting compounds are provided having the formula 1
    Type: Application
    Filed: December 17, 2002
    Publication date: October 23, 2003
    Inventors: Jeffrey A. Robl, David R. Magnin
  • HMG-CoA reductase inhibitors and method
    Patent number: 6627636
    Abstract: Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis and pharmaceutically acceptable salts thereof, wherein X is O, S, SO, SO2 or NR7; Z is n is 0 or 1; R1 and R2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; and R3 to R10 are as defined herein.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: September 30, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventor: Jeffrey A. Robl
  • HMG-CoA reductase inhibitors and method
    Patent number: 6620821
    Abstract: Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis and pharmaceutically acceptable salts thereof, n is 0 or 1; x is 0, 1, 2, 3 or 4; y is 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH2)x and/or (CH2)y together with additional carbons form a 3 to 7 membered spirocyclic ring; R1 and R2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; R3 is H or lower alkyl; R4 and R7 are as defined herein.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: September 16, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventor: Jeffrey A. Robl
  • 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
    Patent number: 6573287
    Abstract: Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where n is 0 or 1; X is H or CN; Y is N, NH or O; Z is CH2 when Y is O or N—H, with Y—Z forming a single bond, and Z is CH when Y is N, with Y—Z forming a double bond; and wherein R1, R2, R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: June 3, 2003
    Assignee: Bristo-Myers Squibb Company
    Inventors: Richard B. Sulsky, Jeffrey A. Robl
  • Heterocyclic containing biphenyl aP2 inhibitors and method
    Patent number: 6548529
    Abstract: aP2 inhibiting compounds are provided having the formula wherein R1, R2, R3, R4, X-Z and are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.
    Type: Grant
    Filed: March 6, 2000
    Date of Patent: April 15, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, Richard B. Sulsky, David R. Magnin
  • Bicyclic modulators of androgen receptor function
    Publication number: 20030055094
    Abstract: The invention provides compounds of the formula I 1
    Type: Application
    Filed: July 31, 2002
    Publication date: March 20, 2003
    Inventors: Chongqing Sun, Jeffrey A. Robl, Mark E. Salvati, Tammy Wang, Lawrence Hamann, David Augeri
  • Pyrazinone inhibitors of fatty acid binding protein and method
    Publication number: 20030040516
    Abstract: aP2 inhibiting compounds are provided having the formula 1
    Type: Application
    Filed: July 12, 2002
    Publication date: February 27, 2003
    Inventors: Richard Sulsky, Jeffrey A. Robl
  • Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
    Patent number: 6518292
    Abstract: Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength. The heterocyclic aromatic compounds have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, wherein Xa is heteroaryl, preferably,  and R1, R1a, R6, Y, Xb, A, B, Z, R3, R4, R4a, R5 and R5a are as defined herein.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: February 11, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Jeffrey A. Robl, Joseph A. Tino, Andres S. Hernandez, James J. Li, Jun Li, Stephen G. Swartz
  • Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors
    Patent number: 6509330
    Abstract: Hydroxamic acids are provided which are ACE and/or NEP inhibitors and have the structure wherein R*, R and R1 are as defined herein and A is a dipeptide preferably derived from an amino acid, or is a conformationally restricted dipeptide mimic.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: January 21, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventor: Jeffrey A. Robl
  • HYDROXAMIC ACID CONTAINING COMPOUNDS USEFUL AS ACE INHIBITORS AND / OR NEP INHIBITORS
    Publication number: 20020193562
    Abstract: Hydroxamic acids are provided which are ACE and/or NEP inhibitors and have the structure 1
    Type: Application
    Filed: February 9, 2001
    Publication date: December 19, 2002
    Inventor: Jeffrey A. Robl
  • 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
    Publication number: 20020183367
    Abstract: Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula 1
    Type: Application
    Filed: March 26, 2002
    Publication date: December 5, 2002
    Inventors: Richard B. Sulsky, Jeffrey A. Robl
  • Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
    Patent number: 6472414
    Abstract: Novel compounds are provided which are inhibitors of MTP and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases, and have the structure including pharmaceutically acceptable salts thereof or prodrug esters thereof, wherein q is 0, 1 or 2; Rx is H, alkyl, aryl or halogen; A is (1) a bond; (2) —O—; or (3) B is: and wherein L2, L1, R1, R2, R3, R3′, R3a, R3b, R4, R4′, R5, X,  are as defined herein.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: October 29, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Scott A. Biller, John K. Dickson, R. Michael Lawrence, David R. Magnin, Michael A. Poss, Jeffrey A. Robl, William A. Slusarchyk, Richard B. Sulsky, Joseph A. Tino
  • HMG-CoA reductase inhibitors and method
    Publication number: 20020094977
    Abstract: Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis 1
    Type: Application
    Filed: December 4, 2001
    Publication date: July 18, 2002
    Inventors: Jeffrey A. Robl, Bang-Chi Chen, Chong-Qing Sun
  • Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
    Publication number: 20020091078
    Abstract: aP2 inhibiting compounds are provided having the formula 1
    Type: Application
    Filed: January 26, 2001
    Publication date: July 11, 2002
    Inventors: Richard Sulsky, Jeffrey A. Robl
  • Pyridone inhibitors of fatty acid binding protein and method
    Publication number: 20020077340
    Abstract: Compounds are provided having the formula 1
    Type: Application
    Filed: November 20, 2001
    Publication date: June 20, 2002
    Inventors: Richard Sulsky, Jeffrey A. Robl
  • Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
    Patent number: 6395767
    Abstract: Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R1, R2, R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor *or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: May 28, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, Richard B. Sulsky, David J. Augeri, David R. Magnin, Lawrence G. Hamann, David A. Betebenner
  • HMG-CoA reductase inhibitors and method
    Publication number: 20020061901
    Abstract: Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis 1
    Type: Application
    Filed: December 4, 2001
    Publication date: May 23, 2002
    Inventors: Jeffrey A. Robl, Bang-Chi Chen, Chong-Qing Sun
  • Method for treating atherosclerosis employing an aP2 inhibitor and combination
    Publication number: 20020035064
    Abstract: A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.
    Type: Application
    Filed: July 13, 2001
    Publication date: March 21, 2002
    Inventors: Jeffrey A. Robl, Rex A. Parker, Scott A. Biller, Haris Jamil, Bruce L. Jacobson, Krishna Kodukula
  • HMG-CoA reductase inhibitors and method
    Publication number: 20020028826
    Abstract: Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis 1
    Type: Application
    Filed: June 6, 2001
    Publication date: March 7, 2002
    Inventors: Jeffrey A. Robl, Bang-Chi Chen, Chong-Qing Sun
  • Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
    Publication number: 20020019411
    Abstract: Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula 1
    Type: Application
    Filed: February 16, 2001
    Publication date: February 14, 2002
    Inventors: Jeffrey A. Robl, Richard B. Sulsky, David J. Augeri, David R. Magnin, Lawrence G. Hamann, David A. Betebenner